Datapoint: AbbVie’s Elahere Gains Full FDA Approval in Ovarian Cancer

The FDA last week granted full approval to AbbVie’s Elahere (mirvetuximab soravtansine-gynx) in certain ovarian cancer patients that have received up to three prior therapies. The antibody-drug conjugate received accelerated approval in November 2022. Phase 3 trial data for Elahere showed that the drug reduced the overall risk of cancer progression by 35%, leading to its full approval. Elahere currently holds covered or better status for 58% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 3/27/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 11

Datapoint: Amylyx Pulls ALS Drug Off the Market

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 10

Datapoint: FDA Grants J&J’s Carvykti Earlier, Expanded Use in Multiple Myeloma

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 9

Datapoint: GA Medicaid Expansion Could Bring Coverage to 300,000 People

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today